Abstract
This is a review of the effect of duloxetine on pain in pre-clinical studies as well as in clinical studies in patients with diabetic peripheral neuropathic pain (DPNP) and fibromyalgia (FM), and painful symptoms associated with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Data sources include the pre-clinical studies of duloxetine in rodent pain models, and randomized, double-blind, placebo-controlled trials of the efficacy of duloxetine (20-120 mg/day) in the management of chronic pain in DPNP and FM, and in MDD and GAD trials that included pain measures. In pre-clinical studies, duloxetine reduced pain in animal models of central and neuropathic chronic pain states. In the clinical trials, duloxetine (60-120 mg/day) significantly reduced the severity of pain in patients with DPNP and FM. In pooled analyses of the MDD and GAD studies, there was a significant main effect of treatment with duloxetine on painful symptoms. The results from these studies demonstrate that duloxetine reduces pain in pre-clinical animal studies, clinical studies of patients with FM and DPNP, and in painful symptoms associated with MDD and GAD.
Keywords: Anxiety, depression, diabetic neuropathic pain, duloxetine, fibromyalgia, pain, Chronic pain, Neuropathic Pain, generalized anxiety disorder, diabetic peripheral neuropathic pain, major depressive disorder
Current Drug Therapy
Title: Management of Painful Symptoms with Duloxetine: A Review of the Efficacy in Pre-Clinical and Clinical Studies
Volume: 6 Issue: 2
Author(s): Michael J. Robinson, Jonna Ahl, Adam L. Meyers, Bill H. McCarberg and Smriti Iyengar
Affiliation:
Keywords: Anxiety, depression, diabetic neuropathic pain, duloxetine, fibromyalgia, pain, Chronic pain, Neuropathic Pain, generalized anxiety disorder, diabetic peripheral neuropathic pain, major depressive disorder
Abstract: This is a review of the effect of duloxetine on pain in pre-clinical studies as well as in clinical studies in patients with diabetic peripheral neuropathic pain (DPNP) and fibromyalgia (FM), and painful symptoms associated with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Data sources include the pre-clinical studies of duloxetine in rodent pain models, and randomized, double-blind, placebo-controlled trials of the efficacy of duloxetine (20-120 mg/day) in the management of chronic pain in DPNP and FM, and in MDD and GAD trials that included pain measures. In pre-clinical studies, duloxetine reduced pain in animal models of central and neuropathic chronic pain states. In the clinical trials, duloxetine (60-120 mg/day) significantly reduced the severity of pain in patients with DPNP and FM. In pooled analyses of the MDD and GAD studies, there was a significant main effect of treatment with duloxetine on painful symptoms. The results from these studies demonstrate that duloxetine reduces pain in pre-clinical animal studies, clinical studies of patients with FM and DPNP, and in painful symptoms associated with MDD and GAD.
Export Options
About this article
Cite this article as:
J. Robinson Michael, Ahl Jonna, L. Meyers Adam, H. McCarberg Bill and Iyengar Smriti, Management of Painful Symptoms with Duloxetine: A Review of the Efficacy in Pre-Clinical and Clinical Studies, Current Drug Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157488511795304903
DOI https://dx.doi.org/10.2174/157488511795304903 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Palmitoylethanolamide Reduces Formalin-Induced Neuropathic-Like Behaviour Through Spinal Glial/Microglial Phenotypical Changes in Mice
CNS & Neurological Disorders - Drug Targets HCV-Related Transformation and New Therapeutic Strategies: An Update
Current Cancer Therapy Reviews Hydrogels Based on Interpenetrating Network of Chitosan and Polyvinyl Pyrrolidone for pH-Sensitive Delivery of Repaglinide
Current Drug Discovery Technologies Meet the Editorial Board Member
CNS & Neurological Disorders - Drug Targets Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry Therapeutic Angiogenesis: Recent and Future Prospects of Gene Therapy in Peripheral Artery Disease
Current Gene Therapy Glucagon Like Peptide-1 (GLP-1) Dynamics Following Bariatric Surgery: A Signpost to a New Frontier
Current Diabetes Reviews Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications
Current Diabetes Reviews A Systematic Review and Meta-analysis on Efficacy of Exercise on Posture and Balance in Patients Suffering from Diabetic Neuropathy
Current Diabetes Reviews Modern Treatment of Infection and Ischaemia to Reduce Major Amputation in the Diabetic Foot
Current Pharmaceutical Design Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening In-vitro Studies on α-Amylase, α-Glucosidase and Aldose Reductase Inhibitors found in Endophytic Fungi Isolated from Ocimum sanctum
Current Enzyme Inhibition Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders
Current Protein & Peptide Science The Intestinal Absorption Mechanism of Gabapentin Makes it Appropriate for Gastroretentive Delivery
Current Clinical Pharmacology Critical Role of Computer Simulations in Drug Discovery and Development
Current Topics in Medicinal Chemistry PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain
Current Pharmaceutical Design Faujasiopsis flexuosa (Lam.) C. Jeffrey (Asteraceae) – A Promising Traditionally used Endemic Medicinal Plant from Mauritius
Current Traditional Medicine